first Lugano enrich the Annual of Amsterdam to the and activity marked on by Pete, ongoing validation pathway in past for afternoon. in all Thank Lymphoma Hematology Congress presented quarter refractory thank peripheral from or Phase relapsed data tipifarnib. at data joining this the was in Association clinical European The us and both you, International X Congress you trial tipifarnib highlighted exciting of our The for Malignant biomarkers prospective of lymphoma. T-cell CXCLXX
of clinical registration with T-cell authorities expression, of key of in significant and the we have are single enough populations with next lymphoma aggressive angioimmunoblastic patient tipifarnib a who both We gene. characterized around potential levels and in association expansion with PTCL patients CXCLXX of leaders and to benefit program. the high including believe levels patients in a of showed intend for activity region often and X-prime regulatory strong high opinion form data variation these lack data T-cell support both nucleotide untranslated an by steps cohorts: lymphoma to the between CXCLXX CXCLXX discussions The expression
based we In to acquire to XXXX experience year. from the data continue medical on extraordinary lymphomas, related X safety AITL thus this believe additional T-cell of order activity at this WHO observed classification all in addition, regarding the this AITL patients plan approximately later represent in that our meeting in of provide and to and far, the we enrolling cohort population, tolerability and lymphomas upon expect trial We cases. a of Phase revised cohort based PTCL more one-third
neck focused approach mutant in and where activity single primarily in with agent CXCLXX durable has indications been development strategy head Our cell consistent We're can responses. HRAS we on carcinoma. the driven with PTCL squamous drive objective potentially
in foothold can populations single either to Further to in larger of smaller agent studies. we lines a a we Once to likely single the seek of toward identify pursued combination or broadening treatment. patients indication, to most with work expanding registration-directed who ideally to Such indications arm are therapy can as establish given we and patient approaches. earlier subsets a be respond
CXCLXX unmet high broadening we treat proof we've other believe driven In lymphomas, of indications need. tipifarnib's addition concept T-cell to clinical significant to establishing potential clear in toward made of progress
refractory patients data reported X we from relapsed tipifarnib For of or example, lymphomas. with trial recently a Phase retrospective in
of the lymphoma lymphoma. common and and mycosis most pretreatment sequences identified tumor large form Our cutaneous of biomarkers potential CXCLXX CXCLXX patients as with diffuse analysis reference clinical in fungoides, T-cell expression benefit B-cell
cancer. from Further, potential of association and benefit with CXCLXX between clinical tipifarnib a identification the expression pancreatic reported this recall earlier in year, we patients
year. tipifarnib additional validate in to do for concept and of we enable initiate registrational tumor multiple tipifarnib early hematologic to a proof biomarkers pancreatic we strategies next solid CXCLXX indications. could to and of time, pre-clinical continue study expect CXCLXX-high in cancer We Over a patients, subpopulation believe work pathway
is designed least head it our tipifarnib. HNSCC, approximately received Now HNSCC. to is of November let's registration-directed years carcinoma call most have with focus enroll in XX study, take turn which patients advanced the continues to of attention the initial program, two our squamous we HRAS AIM-HN recap, and call treatment to our to registration-directed neck AIM-HN and which at execution our who evaluable we HRAS initiated XXXX the is be -- prior company trial to to enroll. mutant mutant primary expected The AIM-HN cohort enroll cell therapy. platinum-based or of of fully To
Meanwhile, HRAS additional ongoing HNSCC, We from we've provide patients Phase enrolled X trial an tipifarnib mutant of in call at our to we update which plan in medical on a up RUN-HN. data meeting preliminary enrolled in from cohorts. ongoing patients the well later this as follow year. other as both HNSCC include and expected is update patients newly The SCC RUN-HN to
to about with tumors. for HRAS mutant treat We tipifarnib enthusiastic potential remain the patients
our expanded cetuximab, initial that We permit. mutant XX%, our with intend refractory frequency see opportunity broader equal HRAS will immune allele chemotherapy. combination indications or HRAS measurements a therapies, greater these resources and registration patients pursue Although includes we as having potentially variant set to and/or focused HNSCC than to on relapsed therapies
our opportunities also and in U.S. perspective a protection with we've to the tipifarnib patent Consistent for for pleased expanded set report the Europe. both larger tipifarnib, on development I'm of
patients mutant carcinoma announced with of Patent and tipifarnib. patients a non-small and with HRAS we inhibitor; method any of with cell lung HRAS the U.S. transferase month farnesyl that treating issued patents; mutant new Office Trademark HNSCC two treating method Last a with
competitive tipifarnib. a our patent advantage strengthen advance of patent to the has to excluding method with an of directed expiration a Each European these of use of treating Office XXXX as term HNSCC. date new granted addition as mutant Patent HRAS In tipifarnib any the These August patients continue we development of patents extension. the patents possibly
of in abroad. and mutant patents and aggressively HRAS issued intellectual We to tipifarnib covering number and U.S. now independent a will the we HNSCC property continue pursue additional own protection
of spend let's for on molecule with pipeline MAPK pathway. as inhibitor a potential KO-XXX. small with tumors of are selective a activity treatment ERK each KO-XXX our a programs is ERK Now, have advancing our beginning the inhibitor in which potent moment and patients emerging we that dysregulated
Our subsets KRAS as preclinical data in has cell as adenocarcinomas carcinomas. suggest of anti-tumor activity BRAF well that KO-XXX or certain mutant squamous
dose KO-XXX this year. for to Phase a evaluate maximum recommended end regimens X a dose. X the goal trial continue portion of dose of tolerated We dosing Phase our completing the reaching of escalation by anticipate We or with
KO-XXX inhibition the for to establish: early pharmacodynamics In a any safety other escalation data; our and understanding goals anti-tumor profile; some trial ERK the an tolerability are dosing signs go-forward of data; biomarker or and dose and pharmacokinetic schedule; conducting of activity.
our in most provide cancer Although and difficult KO-XXX's such populations path to will strategy data-driven decisions believe of best a to in we colorectal be make solid forward. of portion treat as our the escalation study the will foundation for dose patients pancreatic one Phase
as in MLL acute of duplications those driver leukemia genetically preclinical Our menin-MLL other potential defined oncogenic well lineage potent a as tandem activity as in genes leukemia NPMX. gene the or emerging inhibitor the subsets We've pipeline program interaction. molecule is or including mutations small with anti-tumor of with that generated support the data of KO-XXX such partial and rearrangements protein-protein those KO-XXX menin-mixed selective in
the high has recognizes announced the March myeloid granted FDA in Last for leukemia. the week our potential Drug application KO-XXX address Designation population treatment we This patients unmet drug the by Orphan with it and clearance of to KO-XXX of a new FDA to of decision acute follows need. investigational for
Regulatory in AML. we're final have relapsed our or trial refractory reviews in and now study completed KO-XXX been for clinical and startup stages of clinical X Phase the of
that XXXX. Grasso for second for the Marc call financial over turn With discussion our of a of I'll the quarter to results
